Showing results (111-120 of 4,234) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|December 9, 2021
Humoral and cellular correlates of a novel immune-related adverse event and its treatmentAmrit S Gonugunta, Mitchell S von Itzstein, Hong Mu-Mosley, et al.Journal for Immunotherapy of Cancer|January 12, 2022
G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytesChunwan Lu, Dafeng Yang, John D Klement, et al.Journal for Immunotherapy of Cancer|December 13, 2021
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicitiesIlias Christodoulou, Won Jin Ho, Andrew Marple, et al.Journal for Immunotherapy of Cancer|November 24, 2021
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancerSaisha A Nalawade, Paul Shafer, Pradip Bajgain, et al.Journal for Immunotherapy of Cancer|November 26, 2021
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacyMaite Alvarez, Carmen Molina, Carlos E De Andrea, et al.Journal for Immunotherapy of Cancer|December 24, 2021
Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastasesGiuseppe Minniti, Gaetano Lanzetta, Luca Capone, et al.Journal for Immunotherapy of Cancer|January 13, 2022
Immuno-oncology trends: preclinical models, biomarkers, and clinical developmentMaryland Rosenfeld Franklin, Suso Platero, Kamal S Saini, et al.Journal for Immunotherapy of Cancer|January 13, 2022
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinomaWeixiong Yang, Xiangbin Xing, Sai-Ching Jim Yeung, et al.Journal for Immunotherapy of Cancer|March 13, 2021
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapyPascale Hubert, Patrick Roncarati, Stephanie Demoulin, et al.Journal for Immunotherapy of Cancer|November 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsKevin Conlon, Dionysios C Watson, Thomas A Waldmann, et al.Pageof 424